Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2979165 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2979165 Part A, Cohort 1 | EXPERIMENTAL | 20 mg LY2979165 administered orally, daily for 14 days |
| LY2979165 Part A, Cohort 2 | EXPERIMENTAL | 60 mg LY2979165 administered orally, daily for 14 days |
| LY2979165 Part A, Cohort 3 | EXPERIMENTAL | 100 mg LY2979165 administered, orally daily for 14 days |
| LY2979165 Part A, Cohort 4 | EXPERIMENTAL | 150 mg LY2979165 administered orally, daily for 14 days |
| LY2979165 Part B, Cohort 5 | EXPERIMENTAL | Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A |
| LY2979165 Part A, Cohort 6 | EXPERIMENTAL | 250 mg LY2979165 administered orally, daily for 14 days |
| LY2979165 Part A, Cohort 7 | EXPERIMENTAL | 400 mg LY2979165 administered orally, daily for 14 days |
| LY2979165 (Part A) | EXPERIMENTAL | single oral doses at dose levels ranging from 20 to 1000 mg |
| Placebo (Part A) | PLACEBO_COMPARATOR | single oral dose |
| LY2979165 - low dose (Part B) | EXPERIMENTAL | single oral low dose of LY297165 (dose to be determined by Part A) |
| LY2979165 - high dose (Part B) | EXPERIMENTAL | single oral high dose of LY2979165 (dose determined from Part A) |
| Placebo - Part B | PLACEBO_COMPARATOR | single oral dose |
| Name | Type | Description |
|---|---|---|
| LY2979165 | DRUG | Administered orally |
| placebo | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination. Female subjects for Part B (if performed) are at the site's discretion. * Male subjects: Agree to use a reliable method of birth control during the study * Female subjects: Women n...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
LY2979165 is an investigational small molecule developed by Eli Lilly and Company for bipolar disorder. It is a Phase 1 clinical candidate and has not been approved for any indication. Both of its recorded clinical trials have been completed, and no trials are currently active.
LY2979165 targets GRM2, also known as the metabotropic glutamate receptor 2. It acts as an agonist at this receptor. GRM2 agonism is the mechanism under study for its development in bipolar disorder, though the compound remains in early-stage clinical testing.
LY2979165 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound in bipolar disorder.
LY2979165 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. Two Phase 1 trials have been completed, and there are no active trials of LY2979165 at this time.
Two completed Phase 1 trials have evaluated LY2979165: NCT01383967, which enrolled 102 healthy subjects, and NCT01248052, a first-in-human dose study that enrolled 25 healthy volunteers. Both were conducted in Singapore. Together they enrolled 127 participants, and both were randomized, double-blind, and placebo-controlled.
Yes. Both completed Phase 1 trials of LY2979165, NCT01383967 and NCT01248052, enrolled healthy volunteers rather than patients with bipolar disorder. Participants were 21 years of age or older, and the studies took place in Singapore. The trials assessed safety and tolerability of the compound.